Mental and Cognitive Health Library
Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.
Showing 97–120 of 203
Violence Detection AI Reduces Chronic Stress Exposure
This article presents a machine learning framework for detecting violence across multiple contextual levels using hybrid neural network architectures. The relevance to longevity lies in violence prevention and threat detection systems that reduce exposure to acute and chronic stress—a foundational removal of interference that affects nervous system health, immune function, and cardiovascular outcomes.
Microglia protein profiles in CSF across Alzheimer’s disease clinical stages
Analysis of microglial proteins in cerebrospinal fluid identifies distinct molecular signatures across Alzheimer's disease stages, offering potential biomarkers for earlier detection and disease progression tracking. These markers reflect immune cell activation patterns that precede symptomatic decline, enabling more precise stratification of disease trajectory.
Subtyping Alzheimer’s disease and Parkinson’s disease using longitudinal electronic health records
Machine learning analysis of UK health records identifies distinct subtypes of Alzheimer's and Parkinson's disease with shared clinical patterns and divergent genetic signatures. These subtypes enable earlier detection and inform disease-specific intervention strategies, moving beyond one-size-fits-all approaches to neurodegenerative disease management.
AlzeCure presents new preclinical data on NeuroRestore ACD856
ACD856, a first-in-class Trk receptor modulator, demonstrates dose-dependent activation of neurotrophin signaling pathways in preclinical models, with concurrent neuroprotective and antidepressant effects. This mechanism addresses a significant comorbidity pattern in Alzheimer's disease pathology where cognitive decline and mood disturbance are mechanistically linked.
ALZpath cements pTau217 as Alzheimer’s diagnosis frontrunner
ALZpath's pTau217 antibody is establishing itself as a standardized infrastructure tool for blood-based Alzheimer's diagnosis, with 29 presentations at AD/PD 2026 demonstrating reproducibility across multiple research settings and clinical developers. The significance lies not in pTau217's promise alone, but in its emerging role as a scalable, platform-agnostic diagnostic that can integrate into routine medical practice rather than remain confined to specialized labs.
Frailty and Brain Myelin Across Adulthood: Multimodal MRI Insights From the BLSA
Frailty, measured by a validated Frailty Index, correlates with reduced myelin content across white matter tracts in adults from age 22 to 94, with the strongest associations in long-range projection fibers. This multimodal MRI evidence suggests myelin degradation may represent a neural substrate of systemic aging and physiological vulnerability.
[Articles] Delirium, long-term conditions, and incident dementia in older adults admitted to hospital for emergency care in Lothian, Scotland: a population-based cohort study
Delirium during hospitalization carries a substantial dementia risk in older adults, particularly those without multiple long-term conditions. The association suggests delirium represents either a marker of underlying neurodegeneration or a direct contributor to cognitive decline, warranting systematic assessment protocols in acute care settings.
Promoting Adaptation to Caregiving Challenges: A Qualitative Study of Dementia Caregiving Specialists
Dementia caregiving specialists employ structured approaches to help family caregivers develop mastery over the behavioral and emotional challenges of dementia care. Understanding how these specialists facilitate caregiver adaptation provides actionable insights for reducing caregiver burden and improving outcomes in neurodegenerative disease management.
Lecanemab’s next phase: real-world treatment
Lecanemab is transitioning from controlled trials into real-world clinical practice, with Eisai presenting 14 studies on long-term outcomes, administration routes, and early intervention strategies. The data addresses whether cognitive benefits persist over extended periods and whether earlier detection and treatment can alter disease progression in what researchers term 'smoldering' Alzheimer's disease.
[Articles] Multidomain post-stroke cognitive impairment: development and validation of a clinical prediction model
Stroke-specific cognitive prediction models that assess multidomain impairment offer more accurate prognostic value than general cognitive decline models. The binary and continuous versions developed in this research demonstrate generalisability across diverse stroke populations and warrant further domain-specific refinement.
Dementia Tech Design Fails Without Provider Integration
Dementia care technologies proliferate without consistent integration into clinical practice or validation of person-centered design principles. Providers identify gaps between technological capability and practical implementation, pointing to a need for evidence-based adoption frameworks that prioritize functional outcomes over feature complexity.
[Comment] Severe infections consistently linked to dementia?
Severe infections show a persistent association with dementia risk that remains significant even after adjusting for frailty and age-related conditions, suggesting the connection operates through mechanisms independent of pre-existing disease burden. This finding extends prior research and points toward infection-related pathways that directly influence cognitive decline.
Neurotrophic Signaling Drug Passes Safety Threshold for Dementia
AlzeCure's ACD856 completed Phase Ib trials with safety clearance and demonstrated adequate central nervous system penetration at higher doses, establishing dosing parameters for Phase II studies in Alzheimer's disease and depression. The compound's mechanism—enhancing neurotrophic signaling and reducing neuroinflammation—addresses two conditions sharing common pathological underpinnings in neurodegeneration.
Buntanetap gains ground in new Alzheimer’s trial results
Buntanetap showed statistically significant cognitive improvements in early-stage Alzheimer's patients who tested positive for pTau217, reducing multiple disease-related biomarkers including tau, TDP-43, and neuroinflammatory signals. The drug's mechanism of blocking protein production upstream in the disease cascade, rather than targeting single endpoints, represents a shift toward earlier intervention and suggests the field is moving toward precision treatment based on underlying pathology rather than symptom presentation alone.
Examining the Role of Dementia Worry in the Caregiver Burden Process
Dementia worry among family caregivers intensifies caregiver burden through increased stress and emotional strain, with anxiety about personal cognitive decline amplifying the physiological and psychological toll of caregiving responsibilities. This dynamic represents a critical but often-unmeasured pathway through which caregiver stress translates into health deterioration.
Astrocyte-based CAR immunotherapy against Alzheimer’s disease
Engineered astrocytes equipped with chimeric antigen receptor technology can target amyloid-β and tau pathology in Alzheimer's disease models, offering a cell-based immunotherapy approach that addresses hallmark neuropathological features. This represents a distinct mechanistic strategy for modulating neuroinflammation and clearing pathogenic protein aggregates implicated in cognitive decline.
Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease
BIIB080, an antisense oligonucleotide targeting tau protein aggregation, demonstrated favorable trends in slowing cognitive and functional decline in a phase 1b trial of mild Alzheimer's disease patients. These exploratory findings support progression to larger efficacy trials and represent a mechanistic approach to tau-mediated neurodegeneration.
Adequacy, Availability, and Awareness of Alzheimer’s Disease Resources Among Extension Professionals in Texas: Is There an Urban-Rural Divide?
Rural Extension professionals report significant gaps in Alzheimer's disease resources and dementia literacy compared to urban counterparts, with disparities in access to educational materials, diagnostic support, and caregiver services. These findings identify a structural barrier to early detection and management of cognitive decline in populations already at higher risk due to demographic and healthcare infrastructure constraints.
[Articles] Delirium and adverse clinical outcomes: a matched cohort study in the UK Biobank
In-hospital delirium shows a dose-responsive association with adverse long-term clinical outcomes independent of frailty or pre-existing dementia, positioning it as a marker of sustained vulnerability rather than a transient acute event. This distinction matters for risk stratification and post-discharge intervention planning.
Psychosocial Pain Relief in Older Adults: Evidence Gaps
Psychosocial interventions for chronic non-cancer pain in older adults show modest but clinically meaningful effects across cognitive-behavioral therapy, acceptance-based approaches, and mindfulness-based interventions. The evidence base remains fragmented, with heterogeneous outcome measures limiting comparative effectiveness and generalizability to diverse older populations.
NeuroTherapia clears Phase 2a in novel Alzheimer’s treatment
NeuroTherapia's oral Alzheimer's candidate NTRX-07 completed Phase 2a with safety clearance and early signals suggesting effects on neuroinflammation, the chronic immune dysregulation increasingly recognized as a major driver of cognitive decline. The drug targets brain inflammation rather than amyloid alone, representing a shift toward multi-system disease understanding.
The Mediating Role of Sleep Duration in the Association Between Adverse Childhood Experiences and Depressive Symptoms Among Middle-Aged and Older Chinese Adults: A Nationwide Longitudinal Study
Sleep duration mediates the relationship between adverse childhood experiences and depressive symptoms in middle-aged and older adults, suggesting that inadequate sleep represents a mechanistic pathway through which early trauma influences long-term mental health outcomes. This finding identifies a modifiable factor that may interrupt the trajectory from childhood adversity to depression in aging populations.
Purpose and Cognition: Mood Mediates Usefulness Effects
Perceived usefulness to others correlates with better cognitive performance in adults over 50, with this relationship mediated by depressive symptom burden and moderated by cognitive reserve. The finding suggests that psychological sense of purpose operates as a modifiable factor in cognitive aging trajectories.
Cellular mapping strategy repositions neurodegeneration research
The Allen Institute's $400 million Brain Health accelerator shifts neurodegeneration research from protein-focused investigations toward cellular and circuit-level mapping in human brain tissue. This approach targets the architectural vulnerabilities where disease actually initiates, rather than pursuing single molecular culprits that have historically failed to yield effective therapies.